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Heterozygous pathogenic variants in the FN1 gene, encoding fibronectin (FN), have recently been 
shown to be associated with a skeletal disorder in some individuals affected by 
spondylometaphyseal dysplasia with “corner fractures” (SMD-CF). The most striking feature 
characterizing SMD-CF is irregularly shaped metaphyses giving the appearance of “corner 
fractures”. An array of secondary features, including developmental coxa vara, ovoid vertebral 
bodies and severe scoliosis, may also be present. FN is an important extra cellular matrix 
component for bone and cartilage development. Here we report five patients affected by this 
subtype of SMD-CF caused by five novel FN1 missense mutations: p.Cys123Tyr, p.Cys169Tyr, 
p.Cys213Tyr, p.Cys231Trp and p.Cys258Tyr. All individuals shared a substitution of a cysteine 
residue, disrupting disulfide bonds in the FN type-I assembly domains located in the N-terminal 
assembly region. The abnormal metaphyseal ossification and “corner fracture” appearances were 
the most remarkable clinical feature in these patients. In addition, generalized skeletal fragility 
with low-trauma bilateral femoral fractures was identified in one patient. Interestingly, the distal 
femoral changes in this patient healed with skeletal maturation. Our report expands the phenotypic 
and genetic spectrum of the FN1-related SMD-CF and emphasizes the importance of FN in bone 
formation and possibly also in the maintenance of bone strength. 
 

















Metaphyseal ossification irregularities, so called corner fractures, are a typical feature of a subtype 
of autosomal dominant spondylometaphyseal dysplasia (SMD), SMD with “corner fractures” 
(SMD-CF) [MIM: #184255], which was first described as a separate entity in 1990 [1]. 
Previously, COL2A1 mutations were reported in three individuals [2, 3]. Only recently, SMD-CF 
has been linked to mutations in the FN1 gene, encoding fibronectin (FN) [4, 5]. FN is a ubiquitous 
glycoprotein in the extracellular matrix (ECM) with multiple structural and regulatory functions 
[6, 7]. FN forms an insoluble and highly organized matrix that connects cells and other matrix 
proteins such as collagens and glycosaminoglycans to the ECM [8-10]. Through integrin binding, 
FN mediates cellular interactions facilitating migration, proliferation and differentiation [6, 11, 
12]. In the skeleton, FN is important for mesenchymal stromal cells’ (MSCs) condensation, 
migration, proliferation and differentiation, and thereby crucial for cartilage development and 
bone formation [12-16]. 
SMDs comprise a group of genetically and phenotypically heterogeneous bone dysplasias that 
affect the growth plates and the spine. Although most of the clinical features overlap with other 
types of bone dysplasias, SMD-CF presents with some characteristic features. These include 
developmental coxa vara, metaphyseal irregularities, scoliosis, and abnormal ossification at the 
growth plate and secondary ossification sites, which give rise to a “corner-fracture” like phenotype 
[1, 3, 4, 17]. Only eleven patients in eight families with FN1 mutation-related SMD-CF have been 
described thus far [4, 5] and therefore the complete genetic and phenotypic spectrum of the 
disease remains to be more thoroughly characterized. 
As part of our ongoing research on genetic determinants of skeletal dysplasias, we identified five 
new patients with SMD-CF caused by five novel missense mutations in FN1. Here we present the 
















presence of corner fractures as an important diagnostic feature for FN1-related SMD, but also 
underscore the variable severity of the disease, which may lead to diagnostic challenges. Further, 
the presence of femoral fractures and osteopenia in one patient suggests that FN may not only be 
important in the development of skeletal ECM, but might also play a role in bone strength and 
fracture resistance.  
2. SUBJECTS AND METHODS 
2.1 Subjects, Editorial Policies and Ethical Considerations 
One patient with an unknown form of skeletal dysplasia was recruited at the Children's Hospital, 
Helsinki University Hospital, Finland. Four other patients with a similar phenotype were recruited 
through the International Skeletal Dysplasia Society and the GeneDx genetic testing company. 
Ethical approvals for the study were obtained from the Institutional Ethics Boards and complied 
with the World Medical Association Declaration of Helsinki – Ethical Principles for Medical 
Research Involving Human Subjects. A written informed consent to be part of the current research 
study and for editorial purposes was obtained from each participant or his/her legal guardian 
before sample collection. Clinical and radiographic evaluations of all study participants were 
carried out as part of their routine clinical care.  
2.2 Methods 
2.2.1 Clinical and imaging data 
Clinical data were collected retrospectively from hospital records. Anthropometric data were 
compared with appropriate population-based reference values to calculate Z-scores. Radiographs 

















2.2.2 Next generation sequencing (NGS) 
At the onset of this study, FN1 had not been described as a potential candidate gene for SMD. 
Therefore, in four out of the five patients, we used either whole-exome sequencing (WES) or 
whole-genome sequencing (WGS). Genomic DNA was extracted from peripheral blood using 
standard procedures.  
For Patient #1, WGS was carried out at the Science for Life Laboratory (SciLifeLab) in 
Stockholm, Sweden. Library preparation was made using the Illumina TruSeq PCR-free method. 
Clustering was performed by 'cBot' and the libraries were sequenced as 2×150bp paired-end reads 
on the HiSeqX instrument (Illumina) with an average coverage of 30×. Reads were mapped to the 
human genome assembly GRCh37/hg19 with Burrows-Wheeler Aligner (BWA-MEM) [18, 19]. 
Data processing and variant calling were performed according to Genome Analysis Toolkit 
(GATK) best practices [20]. Finally, variants were annotated using Variant Effector Predictor 
(VEP) [21], data were analyzed using GEMINI [22] and candidate variants were manually 
assessed using Integrative Genomics Viewer (IGV).  
For Patient #3, WES was performed at CEGH-CEL- Universidade de São Paulo. Using genomic 
DNA from the proband, the exome was captured using the Illumina TrueSeq kit, and sequencing 
was performed on an Illumina HiSeq 2500. Reads were aligned to the GRCh37/hg19 assembly of 
the human genome with the BWA-MEM aligner. Variant calling included single nucleotide 
variants (SNVs), small insertions and deletions (InDels) and was performed with GATK. The 
resulting data (in variant call format –VCF) were annotated with ANNOVAR [23]. Sanger 
sequencing confirmed the variant in the proband and in her affected mother. 
For Patients #4 and #5, trio WES was conducted at GeneDx. Using genomic DNA from the 
proband and parents, the exonic regions and flanking splice junctions of the genome were captured 
















parallel NGS sequencing was done on an Illumina system with 100bp or greater paired-end reads. 
Reads were aligned to human genome build GRCh37/UCSC hg19, and analyzed for sequence 
variants using a custom-developed analysis tool. Additional sequencing technology and variant 
interpretation protocol has been previously described [24]. The general assertion criteria for 
variant classification are publicly available on the GeneDx ClinVar submission page 
(http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/). 
2.2.3 PCR and Sanger sequencing 
PCR followed by Sanger sequencing according to standard methods was used for targeted gene 
sequencing in one patient and as a validation method for the WGS and WES findings in the other 
patients.  
For Patient #2, Sanger sequencing of exons 1-7 of FN1 was performed from the patient's genomic 
DNA because of phenotypic suspicion, using the primers detailed in Table S1. Sanger sequencing 
was performed at the McGill University and Genome Quebec Innovation Centre. The reads were 
mapped to human FN1 and analyzed using Geneious version R8. Once the mutation was 
identified, genomic DNA from the parents was sequenced for the same exon to demonstrate the de 
novo nature of the mutation. 
3. RESULTS 
3.1. Clinical and radiographic findings 
Based on radiographic evaluation all five patients featured metaphyseal irregularities and “corner 
fracture” appearances, predominantly in proximal and distal tibias, but also in femurs (Fig. 1). 
Four of the patients displayed developmental coxa vara, while all five had genu valgum knee 
abnormalities (Table 1). Scoliosis was seen in three of the five patients, and abnormal vertebral 
















function was normal in all five (Table 1). Detailed clinical information is summarized for each 
patient in Table 1, and some additional clinical information is presented patient-wise below. 
 
Patient #1 This 12.5 year-old boy is the second child of non-consanguineous healthy Finnish 
parents (Table 1, Patient #1). He was born after an uneventful pregnancy and delivery, with 
normal birth measurements. His four siblings are healthy. Development and growth were normal 
during his first year of life. He learned to walk at 14 months and developed a waddling gate. He 
was first evaluated for suspected skeletal disease at 1.8 years of age. Radiographs showed 
metaphyseal irregularities in the long bones and ribs, and coxa vara, while hands, feet and spine 
were normal (Fig. S1). The most prominent metaphyseal changes along with “corner fractures” 
were seen in the distal tibiae and fibulae. He has undergone several surgical procedures to correct 
skeletal deformities, including the severe coxa vara (Table 1). Cognitive development, hearing and 
vision are normal, and abdominal and heart ultrasounds have been normal. Notably, this patient 
sustained bilateral femoral fractures at the age of 3.7 and 3.8 years through low trauma 
mechanisms (Fig. 2B-C). Following conservative treatment fractures healed well without further 
complications. Lumbar spine DXA measurements at 9.6 years of age showed low bone mineral 
density (BMD) (Z-score -2.3). Since 10 years of age he suffers from hip and knee pain and 
receives physiotherapy. At latest appointment he walked independently.  
 
Patient #2 This 6.8 years old boy is the first-born to non-consanguineous Caucasian parents with 
unremarkable family history (Table 1, Patient #2). Short long bones were detected at 20 weeks 
gestation. He was born at 28 weeks of gestation following spontaneous labour, delivered by C-
section for fetal distress. Concerns with short stature were raised at 1.5 years of age. His height 
was 78 cm (-4.1 SD) and he was disproportionate with a normal sitting height. His head 
circumference was on the 25
th
















pointed chin. He had genu varum and walked with a waddling gait. He was reviewed in the 
Genetic Clinic at 3, 4 and 6 years of age. The suspicion of SMD-CF was raised at 6 years based on 
radiographic findings, including widespread metaphyseal irregularities and “corner fractures” 
appearance in the long bones, and vertebral endplate irregularity with anterior sloping (Fig. S2). 
He complained of occasional upper leg and knee pain after prolonged exertion. Genu varum and 
waddling gait have become less prominent with age.  
Patient #3 The proband is a 22 year-old female, the only living child of non-consanguineous 
Brazilian parents (Table 1, Patient #3); the mother, also affected, had two previous miscarriages. 
She was born preterm at 31 weeks. Developmental milestones and cognition were normal. She 
developed bowed legs, progressive difficulty in walking and stunted growth. She was first 
evaluated at 6 years of age, when her height was 105 cm (<5
th
 centile). She displayed rhizomelic 
shortening of upper limbs and bowing of lower limbs, short humeri, coxa vara, irregular 
metaphyses with corner fractures, and abnormal dorsal vertebral bodies. At the age of 19 years her 
height was 127 cm, showing mild kyphoscoliosis with irregular dorsal vertebral bodies, narrowing 
of the intervertebral spaces, short humeri, coxa vara and short femoral neck (Fig. S3).  
The affected mother has short stature and abnormal gait since early childhood. She developed 
progressive, painful joint limitations and kyphoscoliosis, requiring spinal surgery in adulthood. At 
the last evaluation she was wheelchair bound. Her final height is 125 cm. Skeletal survey at 59 
years showed short humeri, coxa vara, osteoarthrosis in the large and interphalangeal joints, spine 
involvement with flattened vertebral bodies and irregularities of C1-C2 (Fig. S3).   
Patient #4 This 14 year-old boy was born by SVD at 35 weeks of gestation to Vietnamese-
American parents from an uncomplicated pregnancy (Table 1, Patient #4). He was seen in 
Genetics first time at 4 years of age for congenital coxa vara. At 4.5 years he displayed short 
















long and phalangeal bones, and possible corner fractures of proximal humeri and tibiae (Fig S4). 
He underwent bilateral proximal femoral valgus osteotomy to correct the coxa vara. This patient 
has a history of additional clinical features. From infancy, he has had vomiting episodes lasting a 
few days, decreasing in frequency, with so far non-revealing work-up. At 4 years of age he was 
diagnosed with high myopia, and at 9 years, borderline elevated intraocular pressures. At 10 years 
of age he received a transfusion for microcytic anaemia (haematocrit: 22.9%) due to iron 
deficiency, which was managed without further episodes of anaemia. Other blood biochemistry 
has been normal. At 11 years serum intact PTH was normal while serum N-terminal telopeptide 
was elevated (66.3 nM BCE/L, normal 5.4-24.2). At age 14, osteocalcin was slightly elevated (54 
ng/ml (normal 3-40)) and N-terminal telopeptide was still elevated (43 nMBCE/L (normal 5.4-
24.2)), while  bone-specific alkaline phosphatase (82 ug/L (normal 78-170)) and beta-CrossLaps: 
1299 pg/ml (normal 240-1734) [25] were normal. He was also found to be hypertensive (blood 
pressure 150/90 mmHg) and has responded well to treatment. Renal function was normal.  
Patient #5 This 32 year-old female presented to the prenatal diagnosis clinic at 23 weeks gestation 
due to fetal risk associated with a family history of autosomal dominant short stature attributed to 
familial metaphyseal dysplasia (Table 1, Patient #5).  Fetal evaluation was considered normal and 
the patient was referred to Medical Genetics to elucidate the etiology of her clinical findings. 
Medical history indicated that the patient was born at 28 weeks of gestation after a pregnancy 
complicated by prenatal diagnosis of bone abnormalities suggestive of skeletal dysplasia. Findings 
included vertebral abnormalities and lower extremity shortening. At birth, coxa vara was 
diagnosed along with lumbosacral vertebral fusions. Family history include similar findings for 
the father, sister and paternal aunt, suggesting an autosomal dominant pattern of segregation. 
Current physical examination shows normal craniofacial shape but asymmetry of the ears with 
















length with rhizomelic shortening of the legs. The patient is currently healthy with no additional 
complications. 
3.2. Genetic findings  
In order to identify the genetic cause of unknown skeletal dysplasia in Patient #1, we carried out 
WGS for the index patient, his healthy parents and his three siblings (two brothers and one sister), 
who were also free from the disease. After applying the following filtering criteria; 1) MAF < 
0.001 in GnomAD [26] and SweGen [27] databases, 2) autosomal recessive/compound 
heterozygous inheritance pattern or de novo variant, and 3) impact severity different than low 
according to GEMINI, we ended up with only one candidate variant: a novel missense 
heterozygous mutation, c.638G>A (p.Cys213Tyr) in FN1 (reference transcript: NM_212482.2; 
ClinVar submission ID: SUB4019866) (Table 2, Fig. 3). This variant was only identified in the 
index patient and thus determined to be a de novo variant. At the time of genetic investigations in 
this family, FN1 mutations had not been reported in patients with SMD-CF. In the other patients 
we used either exome sequencing (Patients #3, #4 and #5) or, after discovery of FN1 mutations in 
SMD-CF, targeted Sanger sequencing of FN1 (Patient #2). We identified four novel heterozygous 
single-nucleotide mutations, c.368G>A (p.Cys123Tyr), c.506G>A (p.Cys169Tyr), c.693C>G 
(p.Cys231Trp) and c.773G>A (p.Cys258Tyr) in FN1 (ClinVar submission ID: SUB4019866) 
(Table 2, Fig. 3). All mutations were de novo except for Patient #3 where the mother is affected 
and Patient #5 where the father is affected, carrying the corresponding mutation (Table 2). Since 
the clinical phenotypes were consistent with the clinical diagnosis of SMD-CF caused by FN1 
mutations we classified these variants as disease-causing in our patients. Moreover, all the 
identified mutations affected highly conserved nucleotides and they were predicted to be 
deleterious according to several in silico bioinformatics tools (Table 2). All these mutations 
















p.Cys258Tyr) in FN type-I domains (Fig. 3). At the protein level, the mutations were predicted to 
destroy disulfide bridges that normally form between these affected cysteine residues and another 
cysteine residue within the same FN type-I domain (UniProt-database, http://www.uniprot.org) 
(Fig. 3B). The loss of a stabilizing intra-domain disulfide bond could result in structural changes 
or instability within the type-1 protein domain, hence disrupt normal protein function. 
 
4. DISCUSSION 
FN plays a major role in the ECM and numerous in vitro studies, supported by some animal 
models, have clearly demonstrated the critical role of FN for MSCs’ differentiation in 
osteogenesis [13-16]
 
as well as chondrogenesis [12, 14]. Still, the importance of FN as a structural 
and functional component of the mature bone matrix and in maintaining a strong skeleton in 
humans is less well understood. Only recently, mutations in FN1 were confirmed as the cause of 
SMD-CF by identifying six heterozygous missense mutations and one three base-pair deletion in 
FN1 [4, 5] in affected patients. 
In this report we identified five novel FN1 mutations in patients with SMD with “corner 
fractures”. All the patients show peculiar metaphyseal changes and “corner fractures”. The “corner 
fractures”, visible on radiographs as lucent areas in the proximal and/or distal metaphyses of tibias 
and/or femurs, represented an important clinical feature in all these patients. This is in line with 
the previous report on FN1 mutations in patients with SMD [4]. “Corner fractures” are triangular 
or curvilinear metaphyseal ossification centers, usually in the proximal and distal femurs and in 
the distal tibias, radiuses and ulnas, resembling microfractures. Metaphyseal changes usually 
present as irregular margins with irregular sclerosis in the adjacent metaphyseal spongiosa. 
Metaphyseal and vertebral changes appear after the first year and persist throughout adolescence 
















“corner fractures” seen in our patients. In most patients, the metaphyseal changes and “corner 
fractures” were visible already in early radiographs (< 3 years of age). 
Novel clinical features reported in the current cohort include bilateral femoral fractures in Patient 
#1. The fractures occurred after low impact trauma, in the distal femurs close to the areas with 
prominent metaphyseal changes. The fractures healed well, and the patient has not sustained 
additional fractures. In addition to the bilateral femoral fractures, Patient #1 presented with rather 
severe bone changes in his distal femurs. Surprisingly, some of these bone changes reversed 
spontaneously and at later follow-up the metaphyseal areas in the femurs have normalized. This 
finding is in line with what has been observed in the patient recently reported by Cadoff et al, who 
featured bilateral corner fractures in both femurs and wrist that resolved over time [5]. A similar 
clinical scenario is typical for metaphyseal anadysplasia, a disease that is characterized by severe 
metaphyseal changes during growth, which resolve spontaneously upon skeletal maturation [29, 
30]. Interestingly, both these diseases have a defective ECM in common. In fact metaphyseal 
anadysplasia is caused by mutations in MMP-9 and MMP-13, encoding the corresponding matrix 
metalloproteinases (MMPs) [29]. These MMPs are important for bone remodeling, repair and 
regeneration through their regulation of ECM turnover [31]. FN is one of the substrates for 
MMPs, and remodeling of FN in ECM is regulated by MMP-mediated cleavage [32], and 
regulation of integrins [33], which are the major FN receptors [33].  It is possible that some 
cysteine substitutions in FN type-I domains render the protein more susceptible to cleavage by 
MMP-9 and MMP-13. Enhanced proteolytic susceptibility has been demonstrated for cysteine 
mutations involved in disulfide bonds in fibrillin-1 leading to Marfan syndrome [34]. 
As a key ECM component, FN regulates the assembly of the collagen I matrix and the 
composition and stability of the ECM [6], which also affects the degree of matrix mineralization 
















a network for deposition of other ECM components. Interestingly, all the novel mutations in this 
report are located within the N-terminal assembly region of FN, and all were found to substitute 
cysteine residues with a hydrophobic amino acid (either tyrosine or tryptophan), which most likely 
destabilizes the structure of the respective FN type-I assembly domains by disrupting intra-domain 
disulfide bridges (Fig. 3) [4]. Five out of seven previously reported mutations describe similar 
cysteine substitutions that affect disulfide bonds in the FN type-I domains (Fig. 3) [4, 5]. Only one 
missense mutation, p.Tyr240Asp, affects an amino acid other than cysteine in the FN type-I 
domain 5 (Fig. 3) [4]. This N-terminal region in FN containing the mutated type-I domains works 
as a separate functional unit that in addition to initiating the fibril assembly, also binds to ECM, 
other proteins and to other regions in FN [8, 10]. Only one patient with SMD-CF harbors a small 
in-frame FN1 deletion that resides outside this region [4]. This three base-pair deletion removes 
threonine 809 in the FN type-III domain 2 (Fig. 3A). Like the FN type-I domains, this domain also 
enhances conformational changes to promote FN assembly [10] and since the patient’s phenotype 
is similar to other patients with missense mutations, the underlying disease mechanism is likely to 
be the same. 
Previous in vitro studies testing two cysteine substitutions, p.Cys87Phe and p.Cys260Gly, and the 
non-cysteine substitution p.Tyr240Asp in HEK293 cells showed that the mutated FN is retained 
within the cells instead of being secreted [4]. More recently, studies on skin fibroblasts of the 
patient with a p.Cys97Trp mutation showed that the mutated FN is preferentially retained in the 
endoplasmic reticulum instead of being secreted thus leading to a reduced production of FN 
matrix compared to control fibroblasts [5]. Furthermore, this patient also shows decreased levels 
of plasma FN. Retained secretion of fibronectin leading to reduced amount of FN in the ECM is a 
possible explanation to the observed skeletal changes seen in our patients with FN1 mutations. 
However, functional studies using osteogenic cells or animal models are needed to better 
















cysteine residues within the FN type-I domains are susceptible to mutations in the FN1 gene, as 
the majority of mutations reported so far are located within this area.  
Although FN1 mutations have also been identified in patients with glomerulopathy with 
fibronectin deposits [MIM: #601894] [37-39], none of our patients had impaired renal function. In 
fact, the mutations previously identified in glomerulopathy with fibronectin deposits cluster on the 
FN type-III domains 
(26-29)
 whereas mutations causing SMD-CF seem to affect the FN type-I 
domains. This indicates that the location of the mutation within the FN protein is crucial for the 
manifestation of either one or the other disease.  
Borderline-high intraocular pressure and hypertension beginning in early childhood were 
identified in Patient #4. Regarding potential for glaucoma, FN seems important for aqueous 
humour outflow [40]. Hypertension was previously noted only during the pregnancy of a 
previously reported patient [4]. In Patient #4, hypertension had an onset in the early childhood and 
has persisted. FN is an important factor for vascular elasticity and its expression is increased in 
hypertension [41], which suggests that abnormal FN might be responsible for increased vascular 
stiffness in this patient. 
FN is crucial for ECM development in a range of tissues, as demonstrated by the embryonic 
lethality of FN knockout in mice [42]. Due to the undisputed stimulating effect on osteogenic and 
chondrogenic differentiation and tissue formation, FN has been highly utilized in tissue 
engineering applications [43-45]. However, the involvement of FN in maintaining bone strength is 
unclear. In our cohort, it is interesting to note that Patient #1 had a decreased lumbar BMD, while 
Patient #4 had increased serum N-terminal telopeptide, suggesting an increased bone turnover 
which might lead to reduced BMD. It is possible that FN1 mutations disrupt normal ECM 
turnover affecting collagen expression or post-translational modification, leading to increased 
















deposition. Using mouse models with conditional deletions of FN in the liver or osteoblasts [46], 
Bentmann et al (2010) demonstrated that plasma FN deposits in bone. Deletion in the liver led to 
decreased mineral and hydroxyapatite content in bone, decreased trabecular bone density, and 
increased collagen fiber diameter in bone. Deletion in osteoblasts did not affect the FN content in 
bone or new bone formation, but increased osteoblast numbers and osteoid volume, indicating an 
altered osteoblast function as the apposition rate was decreased and mineralization delayed. The 
increased collagen fiber size is interesting in view of the COL2A1 mutations found in other 
individuals with SMD-CF. Crosslinking of FN is mediated by transglutaminases, a family of 
crosslinking enzymes. In a recent study, double knock-out of two transglutaminases (TG2 and 
FXIII-A) in mice resulted in altered bone cell differentiation, retention of FN in serum, lower FN 
content in bone, trabecular bone loss and decreased bone strength [47]. This further supports the 
role of functional FN in maintenance of trabecular bone quality. So far, evidence for an 
association between altered FN expression and decreased bone quality in humans is mainly 
derived from studies on increased osteoporosis and fracture risk in patients with severe liver 
diseases [48, 49]. Detailed studies have demonstrated that an altered isoform of FN mediates bone 
loss in these patients [50, 51].  
Our study on metaphyseal bone changes and “corner fractures”, scoliosis, coxa vara, and knee 
abnormalities in patients with novel mutations in FN1, and even bilateral femoral fractures in one 
patient, together with previous reported FN1 mutations in SMD [4], demonstrate the crucial role 
of FN for proper skeletal development and maintenance of  bone strength. Data on BMD and bone 
turnover markers were available only for one patient in our cohort and should be investigated 
more carefully in future studies.  
In summary, we describe here the phenotype of five new patients with SMD-CF, each of whom 
















spectrum of SMD with “corner fractures” and provide for further detailed functional studies for 
elucidating the role of FN in maintaining good bone quality.    
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Figure 1. Corner fractures  
Radiographs show “corner fracture” appearances (arrows) in Patients #1-4 at different ages, in 
hips (A-C), knees (D-E), ankle (F) and wrist (G). Metaphyseal irregularities are also visible.  
 
Figure 2. Femoral fractures and metaphyseal changes in Patient #1. 
A) Abnormal proximal and distal femoral and proximal tibial and fibular metaphyses at 1.9 years 
of age. The femoral necks are short, in varus position and corner fractures can be seen in both hips 
and in the right knee (white arrows). B-C) Bilateral distal femoral fractures (black arrows) at 3.5 
years of age; both femurs have osteopenic appearance. Corner fractures are visible in the right 
distal femur and proximal tibia (white arrows). The distal femoral metaphyses are more regular 
than in A). D) Spontaneous regression of distal femoral metaphyseal changes by 5 years of age. In 
contrast, the metaphyseal changes at proximal tibias and the knee valgus deformity progress with 
age (B-D).  
 
Figure 3. Summary of all the currently identified mutations in the FN1 gene  
A) Schematic illustration of the FN1 exons/domains and location of all currently identified 
mutations causing SMD-CF (red symbols) and glomerulopathy with fibronectin deposits (blue 
symbols), respectively. The five novel mutations described here are indicated above the scheme 
whereas all previously identified mutations appear below. Rectangles represent the exons (1-46) of 
FN1 and are colour coded according to the codified domains. B) Locations of the five novel 
mutations identified in the current study, along with the previously reported mutations affecting 
the fibronectin type-I domains within the N-terminal FN assembly region. All these changes 













Table 1. Skeletal manifestations and clinical features of the five patients with FN1 mutations 
 Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 
Sex Male Male Female Male Female 





38 weeks 28 weeks,  
SROM, LSCS fetal 
distress 
31 weeks, 





Birth weight (g) 




3230 g (-0.5 SD) 
50 cm (-0.6 SD) 
33 cm (-1.7 SD) 
 
1210 g (0.60 SD) 
 
1550 g (0.2 SD) 
40 cm (0.1 SD) 
30 cm (1.4 SD) 
 
2730 g (-1.3 SD) 
48.3 cm (-0.8 SD)  
 
NA 
Age at last assessment 12.5 y 6.8 y 19.3 y 13.8 y 32 y 
Height (cm)
a




















 56.3 cm (+1.0 SD) 51 cm (-0.68 SD) 55 cm (+0.6 SD) 57 cm (+1.6 SD) 56 cm (+1.5 SD) 
Short stature Yes Yes Yes Yes Yes 
Coxa vara  Yes No Yes Yes Yes 
Irregular metaphyses  Yes Yes Yes Yes Yes 
“Corner fractures”  Yes 
Proximal and distal 
femurs, proximal tibias 
present at 1.9 y 
Yes Yes 
In proximal tibia starting 
at 3 y 
Yes 
Distal tibia since 3 y, 
proximal tibia and 
humeri since 4 y 
NA 
Knee anomalies  Genu valgum 
(more severe in the right 
knee) 





No NA Yes  
(right knee and left ankle 
more affected) 
Yes Yes  
Ovoid or abnormal 
vertebral bodies 
No  Yes, 
Biconvex vertebral 
endplates; Anterior sloping 













Scoliosis  Yes (mild) No Yes (mild) No Yes 
Chest anomalies  No No No No NA 
Dental complications Orthodontic treatment 
by dental braces 
NA NA NA NA 
Surgeries Bilateral femoral 
osteotomies for coxa 
vara (at 5.5 y); Posterior 
C1-C2 fusion for 
atlantoaxial instability 
(at 6.5 y); Three 
surgeries to correct 
progressive valgus 
deformity of left tibia (at 
8.0, 10.5 and 11.5 y) 
No No Bilateral femoral 
osteotomies for coxa 
vara (age 4 y) 
Lumbar fusion 
due to abnormal 
vertebrae 
Renal function Normal Normal Normal Normal  Normal 
Main complaints  Pain in hips and knees 
since age 10.5 y 
NA Knees and lumbar pain; 
asymmetric legs 
NA NA 













prematurity, now normal 








y= years; NA= Not available; SROM= Spontaneous rupture of the membranes; LSCS= Low segment Caesarean section; PPROM= Preterm premature rupture 
of the membranes; 
a 















Table 2. Genetic description of the FN1 mutations and bioinformatics prediction of their pathogenicity 
 Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 
Mutation on DNA level† 




































Polyphen probably damaging probably damaging probably damaging probably damaging probably damaging 
SIFT deleterious deleterious deleterious deleterious deleterious 
M-CAP score§ 0.400 0.327 0.382 0.445 0.264 
Mutation type (inherited/de 
novo) 
De novo De novo Inherited (from 
mother) 
De novo Inherited (from father) 
Detection method WGS Sanger sequencing WES WES WES 
†reference sequence: NM_212482.2; ‡Genomic Evolutionary Rate Profiling (GERP) score; §Mendelian Clinically Applicable Pathogenicity (M-



















 We describe 5 novel fibronectin mutations in SMD with “corner fractures” (SMD-CF) 
 All mutations are cysteine substitutions in disulfide bridges of FN type-I domains 
 Abnormal metaphyseal ossification with corner fractures is the hallmark of SMD-CF 
 Bilateral femoral fractures and low BMD were observed in one patient 
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